Is Allarity Therapeutics, Inc. (ALLR) a Buy, Sell, or Hold?
NASDAQ : ALLR
Allarity Therapeutics, Inc.
$1.13 USD
-$0.05 (-4.24%)
- Volume
- 26.56K
- Average Volume
- 198.87K
- Market Capitalization
- $17.98M
- P/E Ratio
- -1.57
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.35
- Year Low
- $0.77
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.23
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Thomas H. Jensen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALLR |
| CUSIP | 016744500 |
| CIK | 0001860657 |
| Web | https://www.allarity.com |
| Phone | 401 426 4664 |
| Currency | USD |
| Employees | 7 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.11 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.23 |
| Quick Ratio | 1.23 |
| Cash Ratio | 0.71 |
Sales & Book Value
| Annual Sales | $320K |
| Price / Sales | 52.11 |
| Cash Flow | -1.05 |
| Price / Cash Flow | -1.08 |
| Price / Book | 2.61 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.78 |
| Trailing P/E Ratio | -1.57 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | -$11.23M |
| Net Margin | -3260.58% |
| Pretax Margin | -3260.58% |
| Return on Equity | -109.94% |
| Return on Assets | -32.21% |
Financials Score
| AltmanZ Score | -5.72 |
| Piotroski Score | 2.00 |
| Working Capital | 6.5M |
| Total Assets | 34.92M |
| Ebit | -10.89M |
| Market Cap | 18.93M |
| Total Liabilities | 28M |
Poll Results
About Allarity Therapeutics, Inc. (NASDAQ:ALLR) Stock
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A li ... posomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
2026-07-07 08:00:00
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity's lead agent, stenoparib Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its in-house laboratory.
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
2026-07-06 10:40:34
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
2026-06-30 08:00:00
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Patent and Trademark Office (USPTO) has granted the key U.S. patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic.
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-26 11:32:12
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
2026-06-19 10:41:26
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.
2026-06-18 08:00:00
Principal Investigator Kathleen N. Moore, M.D.
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
2026-06-03 10:40:27
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
2026-05-15 16:30:00
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP ® companion diagnostic - Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026
Frequently Asked Questions
-
What is the current Allarity Therapeutics, Inc. (ALLR) stock price?
-
Allarity Therapeutics, Inc.(NASDAQ:ALLR) stock price is $1.13 in the last trading session. During the trading session, ALLR stock reached the peak price of $2.35 while $0.769 was the lowest point it dropped to. The percentage change in ALLR stock occurred in the recent session was --4.24% while the dollar amount for the price change in ALLR stock was -$0.05.
-
ALLR's industry and sector of operation?
-
The NASDAQ listed ALLR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALLR?
-
Jeffrey S. Ervin | Chief Financial Officer
Jose L. Iglesias | Consultant Chief Medical Officer
Steen Meier Knudsen | Founder & Chief Scientific Officer
Jeremy R. Graff | President & Chief Development Officer
Thomas H. Jensen | Founder, Chief Executive Officer & Director -
How many employees does ALLR have?
-
Number of ALLR employees currently stands at 7. ALLR operates from 210 Broadway, Boston, MA 02139, US.
-
Link for ALLR official website?
-
Official Website of ALLR is: https://www.allarity.com
-
How do I contact ALLR?
-
ALLR could be contacted at phone #401 426 4664 and can also be accessed through its website. ALLR operates from 210 Broadway, Boston, MA 02139, US.
-
How many shares of ALLR are traded daily?
-
The average number of ALLR shares traded daily for last 3 months was 198.87K.
-
What is the market cap of ALLR currently?
-
The market value of ALLR currently stands at $17.98M with its latest stock price at $1.13